Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of New KCNT1-Epilepsy Drugs by In Silico, Cell, and Drosophila Modeling.

Annals of neurology - 1 Dec 2025

Ricos Michael G, Cole Bethan A, Hussain Rashid, Rychkov Grigori Y, Shaukat Zeeshan, Pilati Nadia, Muench Stephen P, Simmons Katie J, Dibbens Leanne M, Lippiat Jonathan D

Abstract excerpt

OBJECTIVE: Hyperactive KCNT1 potassium channels, caused by gain-of-function mutations, are associated with a range of epilepsy disorders. Patients typically experience drug-resistant seizures and, in cases with infantile onset, developmental regression can follow. KCNT1-related disorders include epilepsy of infancy with migrating focal seizures and sleep-related hypermotor epilepsy. There are currently no...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animals, Genetically Modified
Share to Anticonvulsants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drosophila

Share to Epilepsy

Share to HEK293 Cells

Share to Potassium Channel Blockers

Share to Potassium Channels

Share to Potassium Channels, Sodium-Activated

Source

Open in PubMed Open full text

Identifiers

PMID: 40944494
DOI: 10.1002/ana.78031
PMCID: PMC12682947

Genes

KCNT1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of New KCNT1-Epilepsy Drugs by In Silico, Cell, and Drosophila Modeling.PMID 40944494Read ↗

Identification of new KCNT1-epilepsy drugs by <i>in silico,</i> cell and <i>Drosophila</i> modellingSemantic proximity Read ↗

Large-Scale Structure-Based Virtual Screening Identifies Diverse K <sub>Na</sub> 1.1 (KCNT1) Potassium Channel InhibitorsSemantic proximity Read ↗

Approaches for the discovery of drugs that target K Na 1.1 channels in KCNT1-associated epilepsy.Semantic proximity Read ↗

Discovery of the First Orally Available, Selective KNa1.1 Inhibitor: In Vitro and In Vivo Activity of an Oxadiazole SeriesSemantic proximity Read ↗

Drosophila expressing mutant human KCNT1 transgenes make an effective tool for targeted drug screening in a whole animal model of KCNT1-epilepsy.Semantic proximity Read ↗

Precision therapy with quinidine of KCNT1-related epileptic disorders: A systematic review.Semantic proximity Read ↗

Durable suppression of seizures in a preclinical model of KCNT1 genetic epilepsy with divalent small interfering RNASemantic proximity Read ↗

A comprehensive approach to identifying repurposed drugs to treat SCN8A epilepsy.Semantic proximity Read ↗

New use for an old drug: quinidine in KCNT1-related epilepsy therapy.Semantic proximity Read ↗

Modelling human KCNT1-epilepsy in <i>Drosophila</i> : a seizure phenotype and drug responsesSemantic proximity Read ↗

Discovery of Potent and Selective Blockers Targeting the Epilepsy-Associated KNa1.1 Channel.Semantic proximity Read ↗

Genomics-Guided Precise Anti-Epileptic Drug Development.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.